Breaking News Instant updates and real-time market news.

CLMT

Calumet Specialty Products

$7.95

0.275 (3.58%)

, BOOT

Boot Barn

$21.98

0.48 (2.23%)

18:59
05/15/18
05/15
18:59
05/15/18
18:59

On The Fly: After Hours Movers

UP AFTER EARNINGS: Calumet Specialty Products (CLMT) up 12.6%... Boot Barn (BOOT) up 9.5%... PetIQ (PETQ) up 3.4%. ALSO HIGHER: Teva (TEVA) up 4.7% after increased Berkshire position... Micron (MU) up 0.5% after new stake by Druckenmiller's Duquesne Capital. LOWER: Verastem (VSTM) down 9.9% after equity offering... Calyxt (CLXT) down 6.1% after equity offering... Celyad (CYAD) down 3.3% after equity offering... Party City (PRTY) down 2.0% after equity offering for holders.

CLMT

Calumet Specialty Products

$7.95

0.275 (3.58%)

BOOT

Boot Barn

$21.98

0.48 (2.23%)

PETQ

PetIQ

$19.32

-0.32 (-1.63%)

TEVA

Teva

$20.30

-0.07 (-0.34%)

MU

Micron

$53.99

0.99 (1.87%)

VSTM

Verastem

$5.24

0.09 (1.75%)

CLXT

Calyxt

$16.88

-0.3 (-1.75%)

CYAD

Celyad

$31.00

-2.2 (-6.63%)

PRTY

Party City

$15.35

-0.25 (-1.60%)

  • 15

    May

  • 15

    May

  • 15

    May

  • 16

    May

  • 18

    May

  • 21

    May

  • 30

    May

  • 05

    Jun

  • 12

    Jun

  • 16

    Jun

  • 05

    Oct

  • 16

    May

  • 16

    May

  • 17

    May

  • 18

    May

CLMT Calumet Specialty Products
$7.95

0.275 (3.58%)

03/08/18
03/08/18
NO CHANGE

Calumet Specialty Products calls for redemption of 11.5% Senior Secured Notes
Calumet Specialty Products and its wholly owned subsidiary Calumet Finance have called for redemption of all of the $400M aggregate principal amount of their outstanding 11.5% Senior Secured Notes due 2021. The Partnership expects the redemption to be completed on April 9, and holders will receive a redemption price of 100.0% of the principal amount thereof, plus accrued and unpaid interest thereon up to, but not including, the Redemption Date, plus a Make Whole Premium. Additionally, the Partnership reached an agreement with its lenders for the renewal of its corporate revolving credit facility under a new five-year term.
12/29/17
WELS
12/29/17
NO CHANGE
Target $10
WELS
Outperform
Calumet Specialty Products restructuring remains on track, says Wells Fargo
Wells Fargo analyst Roger Read says Calumet Specialty Products' Q3 results yesterday were weaker than expected as hurricane impacts hurt Specialty Products more than they lifted Fuels' results. The quarter "represented one of those one step backwards amid many forward steps over the prior and coming quarters," Read tells investors in a post-earnings research note. Investors should be disappointed by the weaker results, "but the bigger picture should dominate," the analyst adds. He believes Calumet's restructuring remains on track and that near-term liquidity concerns "have evaporated" following the sale of its Superior refinery and Anchor Drilling Fluids operations. Read reiterates an Outperform rating on the shares with a $10 price target.
09/29/17
WELS
09/29/17
NO CHANGE
Target $10
WELS
Outperform
Calumet Specialty Products price target raised to $10 from $7 at Wells Fargo
Wells Fargo analyst Roger Read raised his price target for Calumet Specialty Products to $10 after hosting meetings with management. The sale of the Superior refinery should result in proceeds in excess of $450M, Read tells investors in a research note. The analyst believes "several favorable developments" have unfolded for Calumet this year, bumping his sum-of-the-parts valuation to $13 from $9. He keeps an Outperform rating on the name.
09/05/17
JANY
09/05/17
DOWNGRADE
JANY
Neutral
Calumet Specialty Products downgraded to Neutral from Buy at Janney Capital
Janney Capital downgraded Calumet Specialty Products to Neutral citing recent share strength.
BOOT Boot Barn
$21.98

0.48 (2.23%)

04/23/18
COWN
04/23/18
INITIATION
Target $22
COWN
Outperform
Boot Barn initiated with an Outperform at Cowen
Cowen analyst Oliver Chen initiated Boot Barn with an Outperform rating, citing an attractive growth rate of 20% based on comp store and digital growth. The analyst said his survey shows customers prefer buying boots at stores but like the company's website and attractive brands. Chen has a $22 price target on Boot Barn shares.
11/15/17
JPMS
11/15/17
UPGRADE
Target $17
JPMS
Overweight
Boot Barn upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Matthew Boss upgraded Boot Barn to Overweight and raised his price target for the shares to $17 from $9. After meeting with management, the analyst believes e-commerce will move from a headwind the past three quarters to a tailwind in the second half of 2017, "translating to a low-to-mid-single-digit same-store-sales story."
01/25/18
PIVT
01/25/18
INITIATION
Target $18
PIVT
Hold
Boot Barn initiated with a Hold at Pivotal Research
Pivotal Research analyst Mitch Kummetz initiated Boot Barn with a Hold rating and a price target of $18. Kummetz says the company is better protected from digital migration among retailers because work boots are in the "buy today wear today" category and the sizing dynamics are more arbitrary relative to laced shoes. The analyst also notes that Boot Barn is not averse to digital based on its domain name and Sheplers acquisitions.
01/11/18
WELS
01/11/18
NO CHANGE
Target $20
WELS
Market Perform
Boot Barn price target raised to $20 from $11 at Wells Fargo
Wells Fargo analyst Tom Nikic raised his price target for Boot Barn to $20 from $11 to reflect tax reform. The analyst reiterates a Market Perform rating on the shares.
PETQ PetIQ
$19.32

-0.32 (-1.63%)

04/13/18
OPCO
04/13/18
NO CHANGE
Target $28
OPCO
Outperform
PetIQ in the process of building credibility among investors, says Oppenheimer
Oppenheimer analyst Brian Nagel told investors in a research note that he came away from a recent meeting with PetIQ CEO Cord Christensen and VIP Petcare CEO Will Santana "incrementally positive." He said the company, which in the short time since its July 2017 IPO has amounted to "one of the more controversial stories among smaller cap consumer positives," is in the process of building credibility among investors and this process takes time. His Outperform rating and $28 price target reflects his intermediate to longer-term confidence in the PetIQ model and senior management, he said.
04/03/18
RHCO
04/03/18
NO CHANGE
Target $30
RHCO
Buy
PetIQ still has long growth runway, says SunTrust
Following the filing of pro forma financials of PetIQ's VIP business, SunTrust analyst William Chappell, Jr. reiterated his Buy rating and $30 price target on the shares, stating that he still sees the company having a long runway of growth ahead for both its products and services businesses.
08/15/17
08/15/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kratos Defense (KTOS) initiated with a Buy at Drexel Hamilton. 2. PetIQ (PETQ) was initiated with an Outperform at Raymond James, William Blair, and Oppenheimer, while being initiated with a Buy at SunTrust and a Hold at Jefferies. 3. Donnelley Financial Solutions (DFIN) initiated with a Neutral at JPMorgan. 4. Calyxt (CLXT) initiated with a Buy at Citi. 5. Ecolab (ECL) initiated with an Equal Weight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/20/17
JEFF
11/20/17
UPGRADE
Target $26
JEFF
Buy
PetIQ upgraded to Buy from Hold at Jefferies
Jefferies analyst Kevin Grundy upgraded PetIQ to Buy saying the recent pullback in shares provides an attractive entry point. In a non-deal roadshow, management conveyed a "high degree of confidence" in the company's outlook, Grundy tells investors in a research note. He believes the short thesis that has emerged "brings little new" information.
TEVA Teva
$20.30

-0.07 (-0.34%)

05/07/18
FBCO
05/07/18
NO CHANGE
Target $23
FBCO
Outperform
Teva turnaround story appears generally on track, says Credit Suisse
Credit Suisse analyst Vamil Divan believes Teva's Q1 earnings were "solid" and sees his bullish thesis on the company as being on track. The analyst notes that the company's restructuring program is proceeding in line with its prior guidance and his expectations, if even a bit ahead of schedule. Divan reiterates an Outperform rating and $23 price target on the shares.
05/03/18
WELS
05/03/18
NO CHANGE
Target $16.5
WELS
Underperform
Teva Q1 'just what investors wanted,' says Wells Fargo
Wells Fargo analyst David Maris believes this quarter is exactly the quarter investors wanted out of Teva, namely progress on the cost cutting and raised guidance on the back of a business that is still facing a significant decline given a tough U.S. generics environment and generic Copaxone pressures. The analyst reiterates an Underperform rating and $16.50 price target on the shares.
04/30/18
DBAB
04/30/18
NO CHANGE
Target $22
DBAB
Buy
Deutsche raises Valeant price target on extended Xifaxan exclusivity
The stay in the Xifaxan litigation between Valeant Pharmaceuticals (VRX) and Teva (TEVA) was recently extended to July 30, 2018 from April 30, 2018, and may be extended further, Deutsche Bank analyst Gregg Gilbert tells investors in an intraday research note. According to the court docket, the companies agreed to extend the stay "because the facts and circumstances that warranted a stay as of May 15, 2017 have not materially changed," Gilbert adds. He previously modeled Xifaxan exclusivity through 2024, but pushed that out one more year saying Teva "does not yet appear to have clarity on the path forward for its generic filing." The exclusivity extension to 2025 on Valeant's largest product pushes the analyst's price target for the shares to $22 from $20. The stock in midday trading is up 19c to $18.26. Gilbert looks forward to an update from Teva when the company reports on May 3 and continues to like the risk/reward for Valeant. He keeps a Buy rating on the shares.
04/27/18
JEFF
04/27/18
NO CHANGE
Target $105
JEFF
Buy
Neurocrine's Ingrezza can beat Q1 estimates, says Jefferies
Jefferies analyst Biren Amin says his firm's fifth proprietary survey on tardive dyskinesia reaffirms that Neurocrine Biosciences' (NBIX) Ingrezza is leading Teva's (TEVA) Austedo in market share for both moderate-severe and mild cases. The analyst thinks Ingrezza can modestly beat consensus estimates for Q1. He keeps a Buy rating on Neurocrine shares with a $105 price target.
MU Micron
$53.99

0.99 (1.87%)

05/15/18
STFL
05/15/18
NO CHANGE
Target $101
STFL
Buy
NAND flash negativity creates buying opportunity in Micron, says Stifel
Stifel analyst Kevin Cassidy said DRAM prices are tracking above his previous estimates for the May-ending quarter, while the NAND flash market "is growing and far from collapsing, as the bear case has it." The NAND flash negativity is overdone, creating buying opportunities in Micron (MU), Smart Global (SGH) and Western Digital (WDC), according to Cassidy. He raised his price target on Micron shares to $101 from $95 while maintaining a Buy rating on the stock. The firm also has Buy ratings on Smart Global and Western Digital.
05/14/18
EVER
05/14/18
NO CHANGE
Target $80
EVER
Outperform
'New' Micron here to stay, says Evercore ISI
Evercore ISI analyst C.J. Muse expects Micron's Analyst Day on May 21 to be heavily focused on the CEO and CFO's plans for the ongoing transformation of the company. Today's Micron is not the Micron of old, and neither is the memory industry, he contends, adding that he expects management to highlight how memory is no longer just a commodity but a critical component in today's third wave of computing. Muse reiterates an Outperform rating and $80 price target on the shares.
05/02/18
MZHO
05/02/18
NO CHANGE
Target $70
MZHO
Buy
Apple offered mixed commentary on memory, says Mizuho
Apple (AAPL) provided mixed commentary on memory on its earnings call last night, Mizuho analyst Vijay Rakesh tells investors in a research note on Micron (MU). While saying inventory was up 75% quarter-over-quarter, Apple also said it sees NAND turning a corner and declining, Rakesh points out. He believes these comments may be counter to what most investors think about DRAM being tight through year-end but close to a peak. However, the analyst says actions speak louder than words. If Apple bought components here, it probably sees tighter NAND and DRAM in the second half of the year, Rakesh argues. He has a Buy rating on Micron with a $70 price target.
04/26/18
STFL
04/26/18
NO CHANGE
STFL
Signs points to continued strong demand for memory, says Stifel
Following the quarterly reports from SK Hynix and Samsung, Stifel analyst Kevin Cassidy said industry data points continue to suggest demand for memory remains strong, primarily from the data center. He also believes memory suppliers continue to act rationally in maintaining incremental supply growth. Cassidy added that his average selling price data in the May quarter to date is tracking ahead of his estimates for both Micron (MU) and SMART Global (SGH).
VSTM Verastem
$5.24

0.09 (1.75%)

03/08/18
RILY
03/08/18
INITIATION
Target $15
RILY
Buy
Verastem initiated with a Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico started Verastem with a Buy rating and $15 price target. The analyst expects the company to "high the ground running" following the new drug application for duvelisib.
05/02/18
GHSC
05/02/18
INITIATION
Target $14
GHSC
Buy
Verastem initiated with a Buy at Seaport Global
Seaport Global analyst Corey Davis initiated Verastem with a Buy and $14 price target saying investors are giving little credit for duvelisib success, despite positive Phase 3 data in chronic lymphocytic leukemia, positive Phase 2 in fillicular lymphoma, and currently being under priority/accelerated FDA review.
12/11/17
OPCO
12/11/17
NO CHANGE
Target $15
OPCO
Outperform
Verastem price target raised to $15 from $6 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target for Verastem to $15 from $6 to reflect decreased risk of failure, now that details of the DUO data are released. Based on the balance of efficacy and adverse events reported from the DUO study, the analyst continues to expect that Verastem will launch duvelisib in 2019, and it will be the primary revenue and earnings driver for the company. The analyst reiterates an Outperform rating on the shares.
11/30/17
ROTH
11/30/17
INITIATION
Target $12
ROTH
Buy
Verastem initiated with a Buy at Roth Capital
Roth Capital analyst Jotin Marango initiated Verastem with a Buy rating and $12 price target, as he believes full CLL data from the DUO pivotal study at ASH next week should bolster investor confidence in duvelisib ahead of an NDA filing he sees as likely in the first quarter of 2018.
CLXT Calyxt
$16.88

-0.3 (-1.75%)

12/20/17
LTCO
12/20/17
INITIATION
Target $34.25
LTCO
Buy
Calyxt initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Jon Hickman started Calyxt with a Buy rating and $34.25 price target.
10/30/17
BMOC
10/30/17
INITIATION
Target $32
BMOC
Outperform
Calyxt initiated with an Outperform at BMO Capital
BMO Capital analyst Kennety Zaslow initiated Calyxt with an Outperform and $32 price target saying it has toe potential to produce disruptive products in the nascent agriculture/crop gene-editing space over the next 10 years.
11/01/17
JEFF
11/01/17
NO CHANGE
Target $27
JEFF
Buy
Calyxt price target raised to $27 from $16 at Jefferies
Jefferies analyst Akshay Jagdale raised his price target for Calyxt to $27 saying that while he wasn't expecting shares to re-rate higher this fast, at current levels the company's pipeline is still being undervalued. Calyxt has scarcity value as the only real pure-play gene editing company focused on the agricultural/consumer industries, Jagdale tells investors in a research note. He keeps a Buy rating on the shares.
04/02/18
SBSH
04/02/18
NO CHANGE
SBSH
Buy
Citi finds FMC management most bullish on Mid-Atlantic tour
After meeting with senior management teams from Air Products (APD), FMC Corporation (FMC), PQ Group (PQG), Calyxt (CLXT) and AgroFresh Solutions (AGFS), Citi analyst P.J. Juvekar says FMC was the most bullish. FMC management highlighted strength in the company's Ag business and the ongoing integration from the DuPont acquisition, Juvekar tells investors in a research note. The analyst raised his estimates for FMC "across the board" on better Ag execution and calls the stock one of our top three ideas. On Air Products, the analyst is "getting more comfortable with the risk/reward of Chinese coal gasification projects." On PQ Group, Juvekar views the recent share pullback as overdone. The company delivered "two solid consecutive quarters" since the initial public offering and has made strides in reducing debt, the analyst contends.
CYAD Celyad
$31.00

-2.2 (-6.63%)

10/09/17
PIPR
10/09/17
NO CHANGE
Target $74
PIPR
Overweight
Celyad price target raised to $74 from $49 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Celyad to $74 after the company last week reported the first ever Morphologic Leukemia-Free Status in an Acute Myeloid Leukemia patient in the first dose cohort of the Phase Ib Think study of CYAD-01 without preconditioning. Fourteen solid and hematologic tumor patients have been dosed in Think and escalation continues with no deaths, Tenthoff tells investors in an intraday research note. He added $258M in value for CYAD-01 in colorectal cancer based on the two patients with stable disease in Think and Celyad's plans to expand enrollment and initiate the Shrink and Link studies. The analyst, who points out his firm has been retained by Celyad as its financial advisor to explore strategic alternatives, reiterates an Overweight rating on the shares.
04/27/18
PIPR
04/27/18
NO CHANGE
Target $74
PIPR
Overweight
Celyad durability of response for CYAD-01 encouraging, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff said he was encouraged by the durability of response, without reports of cytokine release syndrome or neurotoxicity, for a relapsed/refractory Acute Myeloid Leukemia patient 9 months after receiving Celyad's CYAD-01 infusions. Following the publication of the case report, Tenthoff reiterates his Overweight rating and $74 price target on Celyad shares
PRTY Party City
$15.35

-0.25 (-1.60%)

12/27/17
BOFA
12/27/17
NO CHANGE
BOFA
Neutral
Party City accelerated buybacks increase leverage and risk, says BofA/Merrill
BofA/Merrill analyst Curtis Nagle said Party City's $242M repurchase announcement last week from Advent will provide an immediate lift to earnings, but also increases leverage and risk to the business. Nagle raised estimates but reiterated his Neutral rating on Party City shares.
04/19/18
BOFA
04/19/18
UPGRADE
Target $20
BOFA
Buy
Party City upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Curtis Nagle upgraded Party City to Buy from Neutral and raised its price target to $20 from $17 citing expectations for better same-store sales growth in 2019, combined with consistent operating margin expansion. Nagle said a more favorable Halloween calendar, which falls on a Thursday, a strong lineup of franchise firms that will drive increased licensed product sales, and the ongoing acquisition of franchise locations will drive accelerated revenue growth.
11/13/17
11/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Party City (PRTY) assumed with an Overweight at JPMorgan. 2. MongoDB (MDB) was initiated with a Buy at Stifel and Canaccord, an Overweight at Barclays, an Equal Weight at Morgan Stanley, a Market Perform at JMP Securities, and a Neutral at Goldman Sachs. 3. Arista Networks (ANET) initiated with a Neutral at Piper Jaffray. 4. NetScout (NTCT) initiated with an Overweight at Piper Jaffray. 5. Aveo Oncology (AVEO) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/13/17
JPMS
11/13/17
INITIATION
Target $14
JPMS
Overweight
Party City assumed with an Overweight at JPMorgan
JPMorgan analyst Tami Zakaria assumed coverage of Party City with an Overweight rating and $14 price target. The rating is unchanged and the price target is lowered from $18.

TODAY'S FREE FLY STORIES

VIAB

Viacom

$31.87

0.07 (0.22%)

, VIA

Viacom

$36.09

0.76 (2.15%)

20:25
11/15/18
11/15
20:25
11/15/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

VIAB

Viacom

$31.87

0.07 (0.22%)

VIA

Viacom

$36.09

0.76 (2.15%)

HP

Helmerich & Payne

$60.05

1.75 (3.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

  • 16

    Nov

  • 16

    Nov

  • 04

    Dec

TECK

Teck Resources

$22.04

0.9 (4.26%)

20:23
11/15/18
11/15
20:23
11/15/18
20:23
Hot Stocks
Teck Resources announces $400M stock buyback »

Teck Resources Board has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIX

Edison International

$47.07

-6.84 (-12.69%)

20:22
11/15/18
11/15
20:22
11/15/18
20:22
Hot Stocks
Edison International provides update on California fire restoration efforts »

Southern California…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLRX

Valeritas

$0.47

-0.18 (-27.67%)

20:20
11/15/18
11/15
20:20
11/15/18
20:20
Syndicate
Valeritas 75M share Secondary priced at $0.48 »

Valeritas Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVMXY

Avita Medical

$0.00

(0.00%)

20:06
11/15/18
11/15
20:06
11/15/18
20:06
Hot Stocks
Avita Medical to hire U.S. sales team to support national launch of Recell »

AVITA Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SDXAY

Sodexo

$0.00

(0.00%)

20:05
11/15/18
11/15
20:05
11/15/18
20:05
Downgrade
Sodexo rating change  »

Sodexo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CATY

Cathay General

$38.83

0.91 (2.40%)

20:01
11/15/18
11/15
20:01
11/15/18
20:01
Hot Stocks
Cathay General raises quarterly dividend to 31c from 24c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

SUPV

Grupo Supervielle

$8.50

0.42 (5.20%)

19:56
11/15/18
11/15
19:56
11/15/18
19:56
Downgrade
Grupo Supervielle rating change  »

Grupo Supervielle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAAP

Corporacion America Airport

$8.37

0.63 (8.14%)

19:52
11/15/18
11/15
19:52
11/15/18
19:52
Hot Stocks
Corporacion America Airport reports October traffic up 4.5% »

Corporacion America…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$348.37

4.3 (1.25%)

19:43
11/15/18
11/15
19:43
11/15/18
19:43
Periodicals
Tesla aims for Model 3 output of 7K units per week in two weeks, Electrek says »

Tesla has looked to ramp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 13

    Dec

AIV

Aimco

$44.65

-0.46 (-1.02%)

19:26
11/15/18
11/15
19:26
11/15/18
19:26
Hot Stocks
Aimco says California fires have not caused material damage to company »

Apartment Investment and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$239.93

4.83 (2.05%)

19:19
11/15/18
11/15
19:19
11/15/18
19:19
Initiation
Adobe initiated  »

Nomura starts Adobe with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPWR

Ideal Power

$0.39

-0.1505 (-27.87%)

19:16
11/15/18
11/15
19:16
11/15/18
19:16
Downgrade
Ideal Power rating change  »

Ideal Power downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

SONO

Sonos

$14.14

0.17 (1.22%)

, SCVL

Shoe Carnival

$37.03

-1.94 (-4.98%)

19:09
11/15/18
11/15
19:09
11/15/18
19:09
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Sonos…

SONO

Sonos

$14.14

0.17 (1.22%)

SCVL

Shoe Carnival

$37.03

-1.94 (-4.98%)

BGCP

BGC Partners

$10.66

0.24 (2.30%)

SALT

Scorpio Bulkers

$5.71

0.115 (2.06%)

ESEA

Euroseas

$1.65

-0.11 (-6.25%)

NVDA

Nvidia

$202.65

5.43 (2.75%)

WSM

Williams-Sonoma

$60.60

-1.16 (-1.88%)

JWN

Nordstrom

$58.97

-2.125 (-3.48%)

AMAT

Applied Materials

$35.03

1.44 (4.29%)

HTHT

Huazhu Group

$28.59

0.64 (2.29%)

SQ

Square

$73.59

3.74 (5.35%)

NGVC

Natural Grocers

$16.66

0.06 (0.36%)

MCF

Contango Oil & Gas

$4.50

-0.19 (-4.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 16

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

  • 12

    Dec

  • 18

    Dec

DOMO

Domo

$15.96

0.47 (3.03%)

19:04
11/15/18
11/15
19:04
11/15/18
19:04
Hot Stocks
Domo unveils new product suite »

Domo, provider of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PCH

PotlatchDeltic

$36.71

-0.31 (-0.84%)

19:01
11/15/18
11/15
19:01
11/15/18
19:01
Hot Stocks
PotlatchDeltic to pay special dividend of about $3.54 per share »

PotlatchDeltic announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$143.86

-0.39 (-0.27%)

18:54
11/15/18
11/15
18:54
11/15/18
18:54
Periodicals
Senator to ask Facebook about report on treatment of critics, Reuters says »

Senator Amy Klobuchar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

ALRM

Alarm.com

$48.81

0.82 (1.71%)

18:45
11/15/18
11/15
18:45
11/15/18
18:45
Hot Stocks
Alarm.com CEO sells 30K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 26

    Nov

  • 05

    Dec

LAUR

Laureate Education

$14.45

0.3 (2.12%)

18:31
11/15/18
11/15
18:31
11/15/18
18:31
Syndicate
Laureate Education 12.25M share Secondary priced at $14.00 »

Credit Suisse, Barclays,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

PCG

PG&E

$17.77

-7.89 (-30.75%)

18:28
11/15/18
11/15
18:28
11/15/18
18:28
Periodicals
CPUC doesn't want PG&E to go into bankruptcy, Bloomberg says »

A California Public…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

$0.00

(0.00%)

, BITCOIN

Bitcoin

$0.00

(0.00%)

18:24
11/15/18
11/15
18:24
11/15/18
18:24
Periodicals
SEC investigating a company's $50M cryptocurrency sale, WSJ reports »

The SEC is investigating…

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$17.77

-7.89 (-30.75%)

18:23
11/15/18
11/15
18:23
11/15/18
18:23
Hot Stocks
PG&E cut to Baa3 from Baa2 by Moody's, could be cut further »

Moody's downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMB

Limbach Holding

$8.31

-0.14 (-1.66%)

18:10
11/15/18
11/15
18:10
11/15/18
18:10
Hot Stocks
Limbach Holding lowers FY18 EBITDA view to $8M-$10M from $18M-$20M »

Backs FY18 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

NVDA

Nvidia

$202.65

5.43 (2.75%)

18:08
11/15/18
11/15
18:08
11/15/18
18:08
Hot Stocks
Nvidia CEO says the ramp of Turing GPU is 'going great' »

Says Turing represents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

BDRBF

Bombardier

$0.00

(0.00%)

18:06
11/15/18
11/15
18:06
11/15/18
18:06
Hot Stocks
Bombardier intends to fully cooperate with AMF review »

Bombardier said it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.